Literature DB >> 17162210

Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading.

George E Sale1, H Joachim Deeg, Bruce A Porter.   

Abstract

Myelofibrosis is a reactive, often inhomogeneous process in the marrow cavity, and sampling errors on biopsies obtained to diagnose and monitor the course of myelofibrosis have been a constant problem in hematopathology. We investigated the potential utility of magnetic resonance imaging (MRI) of the lumbar spine, pelvis, and femora as a diagnostic and monitoring technique for assessment of myelofibrosis. Findings on serial marrow biopsies were correlated with T1-weighted spin-echo and short inversion time inversion recovery (STIR) images in patients with chronic idiopathic myelofibrosis or myelofibrosis developing from polycythemia vera or essential thrombocythemia who underwent hematopoietic cell transplantation (HCT). Thirty-five patients were studied before HCT; 11 were followed for 3 months and 10 patients for >/=1 year after HCT with sequential marrow biopsies and MRI studies. MRI allowed direct visualization of the biopsy sites and correlation of histologic and MRI findings. MRI also provided assessment of the extent and degree of myelofibrosis in a large volume of the skeletal marrow. There was good correlation between biopsy results and MRI findings at specific biopsy sites and between successful HCT and resolution of fibrosis and osteosclerosis as determined by MRI. We conclude that in patients with myelofibrosis, MRI of the skeleton provides a comprehensive assessment of the pattern and extent of fibrosis and allows for correlation with biopsy findings. In patients undergoing HCT, MRI accurately reflects response or progression of marrow disease.

Entities:  

Mesh:

Year:  2006        PMID: 17162210     DOI: 10.1016/j.bbmt.2006.07.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors:  Haefaa Alchalby; Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

3.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

Authors:  Bart L Scott; Ted A Gooley; Mohamed L Sorror; Andrew R Rezvani; Michael L Linenberger; Jonathan Grim; Brenda M Sandmaier; David Myerson; Thomas R Chauncey; Rainer Storb; Veronika Buxhofer-Ausch; Jerald P Radich; Frederick R Appelbaum; H Joachim Deeg
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

4.  Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.

Authors:  Scott Samuelson; Brenda M Sandmaier; Helen E Heslop; Uday Popat; George Carrum; Richard E Champlin; Rainer Storb; Josef T Prchal; Theodore A Gooley; H Joachim Deeg
Journal:  Br J Haematol       Date:  2011-02-17       Impact factor: 6.998

Review 5.  Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Authors:  Donal P McLornan; Juan Carlos Hernandez Boluda; Tomasz Czerw; Nicholas Cross; H Joachim Deeg; Marcus Ditschkowski; Mufaddal T Moonim; Nicola Polverelli; Marie Robin; Mahmoud Aljurf; Eibhlin Conneally; Patrick Hayden; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2021-05-26       Impact factor: 11.528

Review 6.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 7.  Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.

Authors:  Dae Young Zang; H Joachim Deeg
Journal:  Curr Opin Hematol       Date:  2009-03       Impact factor: 3.284

8.  In vivo magnetic resonance imaging of a mouse model of myelofibrosis.

Authors:  S Matsuura; S Patterson; H Lucero; O Leiva; A K Grant; V L M Herrera; K Ravid
Journal:  Blood Cancer J       Date:  2016-11-11       Impact factor: 11.037

9.  Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis.

Authors:  H Joachim Deeg; Rachel B Salit; Tim Monahan; Gary Schoch; Chris McFarland; Bart L Scott; Barry E Storer
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-18       Impact factor: 5.742

10.  A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.

Authors:  Gary D Luker; Huong Marie Nguyen; Benjamin A Hoff; Craig J Galbán; Diego Hernando; Thomas L Chenevert; Moshe Talpaz; Brian D Ross
Journal:  Tomography       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.